Viela Bio spins off from MedImmune | March 5, 2018 Issue - Vol. 96 Issue 10 | Chemical & Engineering News
Volume 96 Issue 10 | p. 10 | Concentrates
Issue Date: March 5, 2018

Viela Bio spins off from MedImmune

By Ryan Cross
Department: Business
Keywords: Biologics, Viela Bio, MedImmune, AstraZeneca, antibody, autoimmune

Viela Bio, a new company based in Gaithersburg, Md., has spun off from AstraZeneca’s MedImmune subsidiary. Viela will develop biologics for inflammation and autoimmune diseases, starting with three clinical and three preclinical antibodies it is receiving from MedImmune. Viela’s series A funding, potentially worth up to $250 million, was led by three Chinese investment firms: Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment